Axcelis Technologies, Inc. designs, manufactures and services the ion implantation and other processing equipment used in the manufacture of semiconductor chips in the United States, Europe and Asia. The company is headquartered in Beverly, Massachusetts.
| Revenue (TTM) | $866.07M |
| Gross Profit (TTM) | $372.51M |
| EBITDA | $99.39M |
| Operating Margin | 9.43% |
| Return on Equity | 8.89% |
| Return on Assets | 4.12% |
| Revenue/Share (TTM) | $28.00 |
| Book Value | $34.51 |
| Price-to-Book | 3.20 |
| Price-to-Sales (TTM) | 4.10 |
| EV/Revenue | 3.519 |
| EV/EBITDA | 23.63 |
| Quarterly Earnings Growth (YoY) | -23.50% |
| Quarterly Revenue Growth (YoY) | 10.60% |
| Shares Outstanding | $30.88M |
| Float | $30.68M |
| % Insiders | 0.68% |
| % Institutions | 103.64% |
Volatility is currently contracting
BEVERLY, Mass., Sept. 1, 2026 /PRNewswire/ -- Axcelis Technologies, Inc. (NASDAQ: ACLS), a leading supplier of enabling ion implantation solutions for the semiconductor industry, announced the company's plans to participate in the following upcoming investor conferences: The Citi 2026 Global TMT Conference on Tuesday, September 8th at the New York Hilton Midtown.
Investors need to pay close attention to ACLS stock based on the movements in the options market lately.
Axcelis Technologies, Inc. (ACLS) Q2 2026 Earnings Call Transcript
Axcelis Technologies (ACLS) came out with quarterly earnings of $1.06 per share, beating the Zacks Consensus Estimate of $0.9 per share. This compares to earnings of $1.13 per share a year ago.
Axcelis Technologies NASDAQ: ACLS reported second-quarter 2026 revenue of $215 million and non-GAAP diluted earnings per share of $1.06, with both figures exceeding management's expectations. The company raised its outlook for the full year, now expecting mid-single-digit revenue growth after previously forecasting revenue roughly flat with 2025.
Q2 2026 Highlights: Revenue of $215.2 million GAAP Gross Margin of 42.4%, and Non-GAAP Gross Margin of 42.7% GAAP Operating Margin of 9.4% and Non-GAAP Operating Margin of 14.7% GAAP Diluted Earnings Per Share of $0.75, and Non-GAAP Diluted Earnings Per Share of $1.06 BEVERLY, Mass., Aug. 6, 2026 /PRNewswire/ -- Axcelis Technologies, Inc. (Nasdaq: ACLS) today announced financial results for the second quarter ended June 30, 2026.
BEVERLY, Mass., July 29, 2026 /PRNewswire/ -- Axcelis Technologies, Inc. (NASDAQ: ACLS), a leading supplier of enabling ion implantation solutions for the semiconductor industry, announced the company's plans to participate in the following upcoming investor conferences in August: The KBCM Technology Leadership Forum on Monday, August 10th at the Montage Deer Valley, Park City, UT.
System qualified for emerging PMIC device application requiring advanced 15 MeV implant capability BEVERLY, Mass., July 28, 2026 /PRNewswire/ -- Axcelis Technologies, Inc. (Nasdaq: ACLS), a leading supplier of enabling ion implantation solutions for the semiconductor industry, announced today the successful Purion XEmax™ high energy implanter evaluation closure at a leading foundry.
BEVERLY, Mass., July 22, 2026 /PRNewswire/ -- Axcelis Technologies, Inc. (Nasdaq: ACLS), a leading supplier of enabling ion implantation solutions for the semiconductor industry will release financial results for the second quarter of 2026 before the opening of the market on Thursday, August 6, 2026.
In the most recent trading session, Axcelis Technologies (ACLS) closed at $145.01, indicating a +1.95% shift from the previous trading day.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ACLS and any ticker you trade — then tracks every position and per-strategy win rate.
